HMGCR and neoplasm: Statins’ inhibition of HMG-CoA reductase prevents the conversion of HMG-CoA to mevalonate, and thereby reduce levels of mevalonate and its downstream products, probably resulting in control of tumor initiation, growth, and metastasis [56], [57].